Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
Ekaterina Balaian,
Manja Wobus,
Heike Weidner,
Ulrike Baschant,
Maik Stiehler,
Gerhard Ehninger,
Martin Bornhäuser,
Lorenz C Hofbauer,
Martina Rauner,
Uwe Platzbecker
Affiliations
Ekaterina Balaian
Medical Clinic I, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Manja Wobus
Medical Clinic I, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Heike Weidner
Medical Clinic I, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Ulrike Baschant
Medical Clinic III, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;Center for Healthy Aging, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Maik Stiehler
University Centre for Orthopaedics & Trauma Surgery and Centre for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Gerhard Ehninger
Medical Clinic I, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Martin Bornhäuser
Medical Clinic I, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
Lorenz C Hofbauer
Medical Clinic III, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;Center for Healthy Aging, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
Martina Rauner
Medical Clinic III, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;Center for Healthy Aging, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany
Uwe Platzbecker
Medical Clinic I, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;Center for Healthy Aging, University Hospital Carl Gustav Carus Dresden, Heidelberg, Germany;German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
The effects of erythropoietin on osteoblasts and bone formation are controversial. Since patients with myelodysplastic syndromes often display excessively high erythropoietin levels, we aimed to analyze the effect of erythropoietin on osteoblast function in myelodysplastic syndromes and define the role of Wnt signaling in this process. Expression of osteoblast-specific genes and subsequent osteoblast mineralization was increased in mesenchymal stromal cells from healthy young donors by in vitro erythropoietin treatment. However, erythropoietin failed to increase osteoblast mineralization in old healthy donors and in patients with myelodysplasia, whereas the basal differentiation potential of the latter was already significantly reduced compared to that of age-matched controls (P
